From Wikipedia, the free encyclopedia
4-EA-NBOMe Structure.svg
Legal status
Legal status
  • 1-(4-ethylphenyl)-N-[(2-methoxyphenyl)methyl]propan-2-amine
PubChem CID
Chemical and physical data
Molar mass283.415 g·mol−1
3D model (JSmol)
  • InChI=1S/C19H25NO/c1-4-16-9-11-17(12-10-16)13-15(2)20-14-18-7-5-6-8-19(18)21-3/h5-12,15,20H,4,13-14H2,1-3H3

4-EA-NBOMe is a substituted amphetamine and 25-NB derivative which has been sold as a designer drug. It was first identified by a forensic laboratory in Germany in 2014,[1] but while its analytical properties and metabolism have been studied,[2][3][4] its pharmacology remains unknown.

See also[edit]


  1. ^ "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015.
  2. ^ Westphal F, Girreser U, Waldmüller D (September 2016). "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs". Drug Testing and Analysis. 8 (9): 910–9. doi:10.1002/dta.1889. PMID 26606897.
  3. ^ Caspar AT, Westphal F, Meyer MR, Maurer HH (January 2018). "LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques". Analytical and Bioanalytical Chemistry. 410 (3): 897–912. doi:10.1007/s00216-017-0526-0. PMID 28762065. S2CID 206923339.
  4. ^ Caspar AT, Meyer MR, Maurer HH (March 2018). "Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach". Toxicology Letters. 285: 1–8. doi:10.1016/j.toxlet.2017.12.017. PMID 29277574.